DATE: Thursday May 9, 2019 RE: Civil Society Open Letter Regarding Harmful Changes to WHA Transparency Resolution 9 May 2019 – Today more than 100 civil society organizations and health experts sent an open letter to World Health Organization (WHO)… Continue Reading
At the May 7 informal, countries from Northern Europe with strong pharma industry lobbies proposed dozens of changes in the transparency resolution to make it weaker and in many cases confusing and meaningless. This table compares the two texts: Dif-April29-May7-WHA-Transparency-Resolution… Continue Reading
On Monday May 6, 2019, KEI gave the following intervention during the Department of Health and Human Services (HHS) Listening Session in advance of the Seventy-second World Health Assembly to be held in Geneva on May 20-28, 2019. KEI Statement… Continue Reading
On Agenda item 11.7 – Access to medicines and vaccines, KEI offers the following comments on the transparency resolution. 1. Transparency should not be controversial. Policy makers and the public need to have better evidence in order to support policies… Continue Reading
We now keep track of our FOIA requests here. Recent NIH FOIAs: https://www.keionline.org/foia/nih Older logs and pages about selected Freedom of Information Act (FOIA) requests filed by KEI. Centers for Disease Control and Prevention (CDC) March 3, 2015: CDC FOIA… Continue Reading
The WHO has scheduled two information negotiations on the WHA transparency resolution, in Geneva, for May 7 and 10. Below is the revised version of the proposed resolution, that will be discussed at these two meetings. Improving the transparency of… Continue Reading
On April 30, 2019, KEI issued a memorandum to Congress concerning recent proposed measures to cap drug price increases and to increase the transparency of pharmaceutical research and development costs. Congress is currently considering several bills that touch on these… Continue Reading
As the World Health Assembly (WHA) approaches in late May, WHO members will discuss a proposed resolution on transparency. The U.S. Congress is also considering a number bills that would require greater transparency, and groups like KEI have asked the… Continue Reading
University of Oklahoma request for U.S. Manufacturing Waiver for rHA, on the grounds that labor costs would be cheaper in China, and in subject revisions, also in Bulgaria. r_Part1_p0012-21.pdf r_r_r_1524003-01-0013_FOIA_Pratt.pdf r_r_r_UniversityofOklahomaEIR1524003-01-0018-p0009-p0052-3ms.pdf r_r_UniversityofOklahomaEIR1524003-01-0014Part1-p0002-p0010.pdf r_r_UniversityofOklahomaEIR1524003-01-0018-p0001-p0007.pdf r_r_US-Manufacturing-Waiver-1524003-01-0013-4-8-10.pdf 2011, May 5. HHS Approval of… Continue Reading
116th Congress Senate S.102 – Prescription Drug Price Relief Act of 2019 S.366 – FLAT Prices Act S.378 – Stop Price Gouging Act S.474 – Stopping the Pharmaceutical Industry from Keeping drugs Expensive (SPIKE) Act of 2019 S.476 – Creating… Continue Reading